Zydus Lifesciences has been granted a Notice of Compliance (NoC) by Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg strengths. Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily used in the management of hypothyroidism.
The ZDS-Liothyronine tablets will be produced at Zydus’ manufacturing facility in the Ahmedabad SEZ. Liothyronine tablets recorded annual sales of 10.9 million Canadian Dollars in Canada (IQVIA MAT June 2025).
Zydus Lifesciences (formerly Cadila Healthcare), a company limited by shares and incorporated in India, operates as an integrated pharmaceutical company, covering the entire spectrum of the pharmaceutical value chain, including research, development, production, marketing, and distribution of pharmaceutical products.